<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AML1/RUNX1 is implicated in <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> on the basis of the AML1-<z:chebi fb="0" ids="27561">ETO</z:chebi> fusion transcript as well as <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> in its DNA-binding domain </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0001428'>Somatic mutations</z:hpo> in RUNX1 are preferentially detected in <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) M0, <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> with acquired <z:mp ids='MP_0004027'>trisomy</z:mp> 21, and certain <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) cases </plain></SENT>
<SENT sid="2" pm="."><plain>By correlating the presence of RUNX1 mutations with cytogenetic and molecular aberration in a large cohort of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> M0 (N = 90) at diagnosis, we detected RUNX1 mutations in 46% of cases, with <z:hpo ids='HP_0000001'>all</z:hpo> <z:mp ids='MP_0004027'>trisomy</z:mp> 13 cases (n = 18) being affected </plain></SENT>
<SENT sid="3" pm="."><plain>No mutations of NRAS or KIT were detected in the RUNX1-mutated group and FLT3 mutations were equally distributed between RUNX1-mutated and unmutated samples </plain></SENT>
<SENT sid="4" pm="."><plain>Likewise, a high incidence of RUNX1 mutations (80%) was detected in cases with <z:mp ids='MP_0004027'>trisomy</z:mp> 13 from other French-American-British (FAB) subgroups (n = 20) </plain></SENT>
<SENT sid="5" pm="."><plain>As FLT3 is localized on chromosome 13, we hypothesized that RUNX1 mutations might cooperate with <z:mp ids='MP_0004027'>trisomy</z:mp> 13 in <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> by increasing FLT3 transcript levels </plain></SENT>
<SENT sid="6" pm="."><plain>Quantitation of FLT3 transcript levels revealed a highly significant (P &lt; .001) about 5-fold increase in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with RUNX1 mutations and <z:mp ids='MP_0004027'>trisomy</z:mp> 13 compared with samples without <z:mp ids='MP_0004027'>trisomy</z:mp> 13 </plain></SENT>
<SENT sid="7" pm="."><plain>The results of the present study indicate that in the absence of FLT3 mutations, FLT3 overexpression might be a mechanism for FLT3 activation, which cooperates with RUNX1 mutations in <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> </plain></SENT>
</text></document>